krystalbio.com (KRYS) Company Cash Funds

Symbol and logo of brand Krystal Biotech (KRYS)

Krystal Biotech, Inc. (KRYS) is rapidly scaling sales of its first topical gene therapy, leveraging unique cold-chain logistics to protect biomaterials. The company's cash reserve demonstrates financial autonomy, where the 0.91 metric determines the liquidity parameter status. Exclusive rights to orphan drugs and complex dermatology patents guarantee the business's resilience.

Krystal Biotech Inc - KRYS Company Cash Balance (period 07/04/2022 - 11/21/2026)

Analytical breakdowns and data insights for company Krystal Biotech Inc (KRYS)

Analysis of all company metrics:Krystal Corp KRYS
Brand item of Krystal Biotech

This indicator measures the volume of liquid assets, determining the business's ability to cover liabilities and fund expansion without the risk of bankruptcy. By analyzing the company's free cash levels, an investor can assess the resource base of Krystal Biotech, Inc. (KRYS) for the aggressive implementation of innovative gene therapy in dermatology, where a sufficient capital reserve ensures technological dominance and stability during the scaling of commercial sales.